237 related articles for article (PubMed ID: 24500767)
1. A bis(dipyridophenazine)(2-(2-pyridyl)pyrimidine-4-carboxylic acid)ruthenium(II) complex with anticancer action upon photodeprotection.
Joshi T; Pierroz V; Mari C; Gemperle L; Ferrari S; Gasser G
Angew Chem Int Ed Engl; 2014 Mar; 53(11):2960-3. PubMed ID: 24500767
[TBL] [Abstract][Full Text] [Related]
2. Bis(dipyridophenazine)(2-(2'-pyridyl)pyrimidine-4-carboxylic acid)ruthenium(II) hexafluorophosphate: a lesson in stubbornness.
Joshi T; Pierroz V; Ferrari S; Gasser G
ChemMedChem; 2014 Jul; 9(7):1419-27. PubMed ID: 24591361
[TBL] [Abstract][Full Text] [Related]
3. Photolabile ruthenium complexes to cage and release a highly cytotoxic anticancer agent.
Wei J; Renfrew AK
J Inorg Biochem; 2018 Feb; 179():146-153. PubMed ID: 29180165
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, spectroscopic properties, and photoinduced CO-release studies of functionalized ruthenium(II) polypyridyl complexes: versatile building blocks for development of CORM-peptide nucleic acid bioconjugates.
Bischof C; Joshi T; Dimri A; Spiccia L; Schatzschneider U
Inorg Chem; 2013 Aug; 52(16):9297-308. PubMed ID: 23919761
[TBL] [Abstract][Full Text] [Related]
5. Ruthenium Complexes are pH-Activated Metallo Prodrugs (pHAMPs) with Light-Triggered Selective Toxicity Toward Cancer Cells.
Qu F; Park S; Martinez K; Gray JL; Thowfeik FS; Lundeen JA; Kuhn AE; Charboneau DJ; Gerlach DL; Lockart MM; Law JA; Jernigan KL; Chambers N; Zeller M; Piro NA; Kassel WS; Schmehl RH; Paul JJ; Merino EJ; Kim Y; Papish ET
Inorg Chem; 2017 Jul; 56(13):7519-7532. PubMed ID: 28636344
[TBL] [Abstract][Full Text] [Related]
6. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
[TBL] [Abstract][Full Text] [Related]
7. Synthetic strategies towards ruthenium-porphyrin conjugates for anticancer activity.
Gianferrara T; Bratsos I; Iengo E; Milani B; Ostrić A; Spagnul C; Zangrando E; Alessio E
Dalton Trans; 2009 Dec; (48):10742-56. PubMed ID: 20023904
[TBL] [Abstract][Full Text] [Related]
8. Strained ruthenium complexes are potent light-activated anticancer agents.
Howerton BS; Heidary DK; Glazer EC
J Am Chem Soc; 2012 May; 134(20):8324-7. PubMed ID: 22553960
[TBL] [Abstract][Full Text] [Related]
9. DNA intercalating Ru(II) polypyridyl complexes as effective photosensitizers in photodynamic therapy.
Mari C; Pierroz V; Rubbiani R; Patra M; Hess J; Spingler B; Oehninger L; Schur J; Ott I; Salassa L; Ferrari S; Gasser G
Chemistry; 2014 Oct; 20(44):14421-36. PubMed ID: 25213439
[TBL] [Abstract][Full Text] [Related]
10. Towards Light-Activated Ruthenium-Arene (RAPTA-Type) Prodrug Candidates.
Renfrew AK; Karges J; Scopelliti R; Bobbink FD; Nowak-Sliwinska P; Gasser G; Dyson PJ
Chembiochem; 2019 Nov; 20(22):2876-2882. PubMed ID: 31102568
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Medicinal Potential of Two Ruthenium(II) Polypyridine Complexes as One- and Two-Photon Photodynamic Therapy Photosensitizers.
Hess J; Huang H; Kaiser A; Pierroz V; Blacque O; Chao H; Gasser G
Chemistry; 2017 Jul; 23(41):9888-9896. PubMed ID: 28509422
[TBL] [Abstract][Full Text] [Related]
12. Influence of carboxylic acid functionalities in ruthenium (II) polypyridyl complexes on DNA binding, cytotoxicity and antioxidant activity: synthesis, structure and in vitro anticancer activity.
Sathiya Kamatchi T; Chitrapriya N; Kim SK; Fronczek FR; Natarajan K
Eur J Med Chem; 2013 Jan; 59():253-64. PubMed ID: 23234855
[TBL] [Abstract][Full Text] [Related]
13. Molecular and cellular characterization of the biological effects of ruthenium(II) complexes incorporating 2-pyridyl-2-pyrimidine-4-carboxylic acid.
Pierroz V; Joshi T; Leonidova A; Mari C; Schur J; Ott I; Spiccia L; Ferrari S; Gasser G
J Am Chem Soc; 2012 Dec; 134(50):20376-87. PubMed ID: 23181418
[TBL] [Abstract][Full Text] [Related]
14. A ruthenium(II) arene complex showing emission enhancement and photocleavage activity towards DNA from singlet and triplet excited states respectively.
Chen Y; Lei W; Jiang G; Zhou Q; Hou Y; Li C; Zhang B; Wang X
Dalton Trans; 2013 Apr; 42(16):5924-31. PubMed ID: 23459918
[TBL] [Abstract][Full Text] [Related]
15. Anticancer activity of opened arene ruthenium metalla-assemblies.
Barry NP; Zava O; Furrer J; Dyson PJ; Therrien B
Dalton Trans; 2010 Jun; 39(22):5272-7. PubMed ID: 20442944
[TBL] [Abstract][Full Text] [Related]
16. Monomeric and dimeric coordinatively saturated and substitutionally inert Ru(ii) polypyridyl complexes as anticancer drug candidates.
Notaro A; Gasser G
Chem Soc Rev; 2017 Nov; 46(23):7317-7337. PubMed ID: 29027562
[TBL] [Abstract][Full Text] [Related]
17. Heterodinuclear Pt(iv)-Ru(ii) anticancer prodrugs to combat both drug resistance and tumor metastasis.
Ma L; Ma R; Wang Z; Yiu SM; Zhu G
Chem Commun (Camb); 2016 Sep; 52(71):10735-8. PubMed ID: 27506281
[TBL] [Abstract][Full Text] [Related]
18. A hypoxia efficient imidazole-based Ru(II) arene anticancer agent resistant to deactivation by glutathione.
Purkait K; Karmakar S; Bhattacharyya S; Chatterjee S; Dey SK; Mukherjee A
Dalton Trans; 2015 Apr; 44(13):5969-73. PubMed ID: 25742181
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and Biological Evaluation of Ru(II) and Pt(II) Complexes Bearing Carboxyl Groups as Potential Anticancer Targeted Drugs.
Martínez MÁ; Carranza MP; Massaguer A; Santos L; Organero JA; Aliende C; de Llorens R; Ng-Choi I; Feliu L; Planas M; Rodríguez AM; Manzano BR; Espino G; Jalón FA
Inorg Chem; 2017 Nov; 56(22):13679-13696. PubMed ID: 29099179
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, structure and biological evaluation of ruthenium(III) complexes of triazolopyrimidines with anticancer properties.
Fandzloch M; Dobrzańska L; Jędrzejewski T; Jezierska J; Wiśniewska J; Łakomska I
J Biol Inorg Chem; 2020 Feb; 25(1):109-124. PubMed ID: 31741123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
